Loading
Life sciences · Journal article
Current Therapeutic Research, Clinical and Experimental · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background. Antinuclear antibodies (ANA) are among the most commonly used tests in autoimmune disease but are frequently positive in healthy individuals, with uncertain significance. Reported prevalence ranges from under 6% to over 45% across populations, and its determinants in healthy individuals are poorly defined.Objective. We examined ANA prevalence and its demographic and lifestyle correlates in a community sample in Japan.Methods. Serum samples were obtained from 1,017 community residents in a single prefecture in Japan. Age and sex were recorded for all participants; smoking status and allergic history were available for a subset (n = 467). ANA were measured by indirect immunofluorescence on HEp-2 cells; a 1:40 titer defined positivity. Associations were assessed using chi-square tests, logistic regression with linear and quadratic age terms, and multivariable logistic regression adjusting sequentially for age, sex, smoking, and allergic history.Results. Among 1,017 participants (542 women and 475 men), overall ANA positivity was 18.3% (186/1,017). Positivity was significantly higher in women than in men (21.8% vs. 14.3%) and showed a U-shaped age pattern in women. ANA positivity was not associated with allergic history. Exploratory subgroup analysis showed higher positivity in current or former smokers than never-smokers among men. After adjustment for age, female sex was independently associated with ANA positivity (OR 1.72, 95% CI 1.24-2.40). In the lifestyle subset, female sex was the only independently associated factor after adjustment for age, smoking status, and allergic history.Conclusions. These data provide a population-specific baseline for ANA positivity in a Japanese community sample and confirm that prevalence is higher in women and varies with age. Because ANA is frequently measured and may precede autoimmune disease, longitudinal studies are needed to clarify whether incidental positivity in healthy individuals carries prognostic significance.